Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation

Detalhes bibliográficos
Autor(a) principal: Lamela-Gómez, Iván
Data de Publicação: 2023
Outros Autores: Gonçalves, Lídia, Almeida, António José, Luzardo-Álvarez, Asteria
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/61036
Resumo: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
id RCAP_5b9922aebeacb2b307062445f0b46a44
oai_identifier_str oai:repositorio.ul.pt:10451/61036
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluationInfliximabMicroencapsulationRheumatoid arthritisIntra-articularControlled releaseMonoclonal antibodiesOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Microencapsulation of the therapeutical monoclonal antibody infliximab (INF) was investigated as an innovative approach to improve its stability and to achieve formulations with convenient features for intra-articular administration. Ultrasonic atomization (UA), a novel alternative to microencapsulate labile drugs, was compared with the conventional emulsion/evaporation method (Em/Ev) using biodegradable polymers, specifically Polyactive® 1000PEOT70PBT30 [poly(ethylene-oxide-terephthalate)/poly(butylene-terephthalate); PEOT-PBT] and its polymeric blends with poly-(D, L-lactide-co-glycolide) (PLGA) RG502 and RG503 (PEOT-PBT:PLGA; 65:35). Six different formulations of spherical core–shell microcapsules were successfully developed and characterized. The UA method achieved a significantly higher encapsulation efficiency (69.7–80.25%) than Em/Ev (17.3–23.0%). Mean particle size, strongly determined by the microencapsulation method and to a lesser extent by polymeric composition, ranged from 26.6 to 49.9 µm for UA and 1.5–2.1 µm for Em/Ev. All formulations demonstrated sustained INF release in vitro for up to 24 days, with release rates modulated by polymeric composition and microencapsulation technique. Both methods preserved INF biological activity, with microencapsulated INF showing higher efficacy than commercial formulations at comparable doses regarding bioactive tumor necrosis factor-alpha (TNF-α) neutralization according to WEHI-13VAR bioassay. Microparticles’ biocompatibility and extensive internalization by THP-1-derived macrophages was demonstrated. Furthermore, high in vitro anti-inflammatory activity was achieved after treatment of THP-1 cells with INF-loaded microcapsules, significatively reducing in vitro production of TNF-α and interleucine-6 (Il-6).Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Iván Lamela-Gómez received funding from the “Axudas á etapa predoutoral da Xunta de Galicia, cofinanciadas polo programa operativo FSE Galicia 2014–2020” predoctoral grant program. Consellería de Cultura, Educación e ordenación universitaria, Xunta de Galicia, Spain. This research was partially funded by Consellería de Cultura, Educación e ordenación universitaria, Xunta de Galicia, Spain. Axudas para a consolidación e estructuración de unidades de investigación competitivas Modalidad A: Grupos de Referencia Competitiva (ED341C 2017/13). This research was also partially funded by the Fundação para a Ciência e a Tecnologia (FCT), Portugal (UID/DTP/04138/2019 and UIDB/04138/2020 to iMed.ULisboa), and principal investigator grants CEECIND/03143/2017 (L. M. Gonçalves).SpringerRepositório da Universidade de LisboaLamela-Gómez, IvánGonçalves, LídiaAlmeida, António JoséLuzardo-Álvarez, Asteria2023-11-30T13:20:20Z2023-122023-11-22T19:44:07Z2023-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/61036engLamela-Gómez I, Gonçalves LM, Almeida AJ, Luzardo-Álvarez A. Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation. Drug Deliv and Transl Res. 2023;13(12):3030–58. Disponível em: https://link.springer.com/10.1007/s13346-023-01372-1cv-prod-340604510.1007/s13346-023-01372-1info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-04T01:18:25Zoai:repositorio.ul.pt:10451/61036Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:40:48.342370Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
title Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
spellingShingle Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
Lamela-Gómez, Iván
Infliximab
Microencapsulation
Rheumatoid arthritis
Intra-articular
Controlled release
Monoclonal antibodies
title_short Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
title_full Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
title_fullStr Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
title_full_unstemmed Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
title_sort Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis in vitro evaluation
author Lamela-Gómez, Iván
author_facet Lamela-Gómez, Iván
Gonçalves, Lídia
Almeida, António José
Luzardo-Álvarez, Asteria
author_role author
author2 Gonçalves, Lídia
Almeida, António José
Luzardo-Álvarez, Asteria
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Lamela-Gómez, Iván
Gonçalves, Lídia
Almeida, António José
Luzardo-Álvarez, Asteria
dc.subject.por.fl_str_mv Infliximab
Microencapsulation
Rheumatoid arthritis
Intra-articular
Controlled release
Monoclonal antibodies
topic Infliximab
Microencapsulation
Rheumatoid arthritis
Intra-articular
Controlled release
Monoclonal antibodies
description Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
publishDate 2023
dc.date.none.fl_str_mv 2023-11-30T13:20:20Z
2023-12
2023-11-22T19:44:07Z
2023-12-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/61036
url http://hdl.handle.net/10451/61036
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Lamela-Gómez I, Gonçalves LM, Almeida AJ, Luzardo-Álvarez A. Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation. Drug Deliv and Transl Res. 2023;13(12):3030–58. Disponível em: https://link.springer.com/10.1007/s13346-023-01372-1
cv-prod-3406045
10.1007/s13346-023-01372-1
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136312766234624

Registros relacionados